Battistini A
Centro di Fisiopatologia Respiratoria Infantile, Università di Parma, Italia.
Pediatr Med Chir. 2000 Jul-Aug;21(4):171-9.
Of the four treatments that can be used to treat respiratory insufficiency due to laryngitis, two, nebulized adrenaline and O2 therapy, are undoubtedly effective. The inhalation of water vapour appears to be increasingly useless and may be also harmful. The use of steroids is still under debate. In recent literature, however, the utility of steroids seems to be confirmed, especially if administered per Os, and even at a relatively low single oral dose (1-2 mg/kg of prednisone). According to the official organs (see Red Book) and according to the Evidence Based Medicine (see Cochrane Library) the treatment of bronchiolitis should be limited to an eventual support therapy, i.e. O2 therapy and rehydration. However, the approach adopted by North American Hospitals and European specialists in infectious diseases is in contrast and consists in the use of beta 2 agonists and steroids in 90-100% and 40-80% of patients, respectively. This contrast could be due to a deficiency in the researches of the Evidenced Based Medicine which is obliged to retrieve studies done over 10-15 years in order to obtain a sufficient number of data for a statistically valid investigation. These studies unfortunately are not updated with regard to the dose of individual drugs and the immediate association of drugs. In particular, with regard to nebulized beta 2 agonists, the absence of a positive effect could be due to an excessively low dose in relation to the age of the patient. According to the most recent knowledge, in fact, reduced doses are no longer required for babies in consideration of age and weight. In reality an equal and even higher dose than that used in adults would be best. The other reason for a lack of response could be the absence of the association of a steroid with a beta 2 agonists at the right moment. The lack of timing in associating these two drugs could also account for the absent response to the steroid. On the basis of these considerations it would be a mistake to give up the use of beta 2 agonists and steroids. Considering also the severity and frequency of a disease as bronchiolitis. To follow the "fashion" of the Evidence Based Medicine. Recently, magnesium sulphate, ketamine and the association elium-O2 have been suggested as marginal and not revolutionary medical interventions for the treatment of asthma. Among bronchodilators, the subordinate role of anticholinergics (for ex. ipratropium bromide), and of adrenaline has been defined with respect to beta 2 agonists, in particular salbutamol. The optimisation of the administration by nebulizers of the latter has been fundamental as it has a key role in the treatment of acute severe asthma. In detail, traditional nebulizers tend to be substituted by Metered Dose Inhaler + spacer with a ratio in the dose of 5/1. The venous route is used only in very severe cases and is used late and in intensive care although a single initial intravenous administration could determine a more rapid reduction of bronchoconstriction and reduce the number of nebulized bronchodilatators that can become extremely frequent in most severe cases. For steroids, instead, the only safe therapeutic route is by PO, i.v., i.m.: nebulized steroids although used with a definitely higher dose than that used for chronic asthma, can be used only in the milder forms.
在可用于治疗喉炎所致呼吸功能不全的四种治疗方法中,有两种,即雾化肾上腺素和氧气疗法,无疑是有效的。吸入水蒸气似乎越来越无用,甚至可能有害。类固醇的使用仍存在争议。然而,在最近的文献中,类固醇的效用似乎得到了证实,尤其是口服给药时,甚至单剂量相对较低(泼尼松1 - 2毫克/千克)时。根据官方机构(见《红宝书》)以及循证医学(见《考科蓝图书馆》),毛细支气管炎的治疗应限于必要的支持性治疗,即氧气疗法和补液。然而,北美医院和欧洲传染病专家所采用的方法却与之相反,分别有90% - 100%的患者使用β2激动剂,40% - 80%的患者使用类固醇。这种差异可能是由于循证医学研究存在缺陷,为了获得足够数量的数据进行具有统计学意义的调查,它不得不检索10 - 15年前进行的研究。不幸的是,这些研究在个别药物剂量和药物的即时联合使用方面并未更新。特别是对于雾化β2激动剂,没有产生积极效果可能是因为相对于患者年龄剂量过低。事实上,根据最新知识,考虑到年龄和体重,婴儿不再需要减少剂量。实际上,给予与成人相同甚至更高的剂量可能是最佳选择。缺乏反应的另一个原因可能是没有在合适的时间将类固醇与β2激动剂联合使用。这两种药物联合使用的时机不当也可能导致对类固醇没有反应。基于这些考虑,放弃使用β2激动剂和类固醇将是一个错误。考虑到毛细支气管炎这种疾病的严重性和发病率。遵循循证医学的“潮流”。最近,硫酸镁、氯胺酮以及氦氧混合气被认为是治疗哮喘的边缘且并非革命性的医学干预措施。在支气管扩张剂中,已明确抗胆碱能药物(如异丙托溴铵)和肾上腺素相对于β2激动剂,特别是沙丁胺醇的次要作用。优化后者通过雾化器给药至关重要,因为它在急性重度哮喘的治疗中起关键作用。具体而言,传统雾化器往往被定量吸入器 + 储物罐所取代,剂量比为5/1。静脉途径仅在非常严重的情况下使用,且使用较晚且在重症监护中使用,尽管单次初始静脉给药可更迅速地减轻支气管收缩,并减少在大多数严重情况下可能极为频繁使用的雾化支气管扩张剂的次数。对于类固醇,相反,唯一安全的治疗途径是口服、静脉注射、肌肉注射:雾化类固醇尽管使用剂量肯定高于慢性哮喘,但仅可用于较轻的病例。